AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-15
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(0) · ALS(0) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(0) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
No new qualifying paper for this issue.
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Deep Brain Stimulation (DBS) is an invasive procedure used to alleviate motor symptoms in Parkinson's Disease (PD) patients. Despite its effectiveness, the impact of DBS on brain activity and the way to optimise stimulation parameters remains unclear. In this study, we aimed to map the sensitivity of cortical neural response to changes in DBS parameters in real-world clinical settings. We recorded in-clinic EEG data from PD patients during their clinical DBS programming sessions, both at rest and during arm movement. A siamese variant of the EEGNet deep learning architecture was trained independently for each patient and parameter combination to determine whether two 1-sec-long EEG segments were recorded under the same or different DBS parameters, yielding 30 independently trained models. Our models achieved an average accuracy of 74% in classifying whether two 1-second EEG segments corresponded to the same or different DBS parameters. Explainability methods were then applied to extract the neural oscillations learned by the models. Ablation studies identified mid-gamma oscillations (55-90Hz) as the key band for classifying these changes. Importantly, that was not driven by 1:2 gamma entrainment. In a sub-group of patients, the theta-alpha oscillations (4-12Hz) also contributed to detecting changes in DBS parameters. We demonstrate that small DBS parameter changes modify cortical activity in a consistent manner that can be detected using shallow convolutional networks on low-density EEG. Our findings suggest that cortical mid-gamma oscillations (55-90Hz) are highly sensitive to small changes in DBS settings. Our approach and findings could be leveraged towards identifying and defining novel digital biomarkers to guide DBS programming and adaptive DBS systems.
Journal IF-equivalent: 5.2 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Peiro NC, Haugland MR, Kutuzova A, Graef C, Bocum A, Tai YF, et al. EEG-based Deep Learning Reveals Cortical Sensitivity to Small Changes in Deep Brain Stimulation Parameters. Neuroimage. 2026 Nov [Epub ahead of print]. doi:10.1016/j.neuroimage.2026.122354. PMID: 43025559.Checked: Abstract only - Abstract
Confirmatory labels for Parkinson's disease (PD), from expert examination or, prospectively, biological assays, are costly, and missed cases and false alarms carry unequal consequences. ClinRisk-LLM is a framework for label-efficient, cost-aware learning from gait and speech signals in which a large language model (LLM) translates a predefined safety specification into a frozen policy setting the positive-class weight of a support vector machine and the priority of potential missed cases for annotation. Cost-sensitive training, risk-aware querying and the LLM policy were ablated on gait (n=165) and speech (n=252) data and benchmarked against post hoc thresholding, a refer-all policy, held-out gait studies and an independent speech cohort. With half of the labels, cost-sensitive active learning reduced the 4:1 asymmetric cost by 34.1% (gait) and 5.7% (speech) relative to standard active learning, at the expense of specificity. ClinRisk-LLM translated the predefined safety specification into a frozen, auditable policy that adjusted risk settings during label acquisition. Component-wise analyses indicated that classifier weighting accounted for most of the observed cost reduction, while the incremental benefit of LLM-guided adaptation varied across datasets and comparison settings. A threshold-tuned symmetric model came within 1.3 cost points for gait, and gait remained roughly level with referring everyone. ClinRisk-LLM reached a gait cost of 47.60 versus 46.10 for fixed cost-sensitive learning; 40 policies generated across three LLMs from a reconstructed specification yielded gait costs of 52.1-75.8. Applications to molecular triage remain prospective. Code and data availability details are provided in the Data Availability Statement.
Journal IF-equivalent: 8.2 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Gülez B, Güneş A, Kocabıçak E. LLM-Guided Adaptive Cost Calibration in Active Learning for Parkinson’s Disease Biosignals. Int J Mol Sci. 2026 Oct 25;27(21):9542. doi:10.3390/ijms27219542. PMID: 43027796.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
No new qualifying paper for this issue.
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.